Article Text

Download PDFPDF
Association between pancreatic cancer and metformin use in patients with type 2 diabetes
  1. Shih-Wei Lai1,2,
  2. Chia-Hsun Tsai3,
  3. Cheng-Li Lin1,4,
  4. Kuan-Fu Liao3,5
  1. 1 College of Medicine, China Medical University, Taichung city, Taiwan
  2. 2 Department of Family Medicine, China MedicalUniversity Hospital, Taichung city, Taiwan
  3. 3 Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung city, Taiwan
  4. 4 Management Office for Health Data, China Medical University Hospital, Taichung city, Taiwan
  5. 5 College of Medicine, Tzu Chi University, Hualien, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao, Taichung Tzu Chi Hospital, Taichung City 427, Taiwan; kuanfuliaog{at}gmail.com

Statistics from Altmetric.com

One cohort study revealed that patients with type 2 diabetes with metformin use had a lower risk of developing pancreatic cancer (HR 0.49, 95% CI 0.25 to 0.96).1 One meta-analysis revealed that patients with type 2 diabetes with metformin use had a lower mortality of pancreatic cancer (risk ratio 0.84, 95% CI 0.73 to 0.96) .2 However, one cohort study revealed no significant association between metformin use and pancreatic cancer (HR 0.85, 95% CI 0.39 to 1.89).3 Another cohort study revealed no significant association between metformin use and survival of pancreatic cancer (HR 0.86, 95% CI 0.66 to 1.11).4 Conflicting findings exist on this issue. In order to clarify these debates, a population-based case–control study was designed to analyse the database of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.